Skip to main content

Published locations for Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis

User login

  • Reset your password
  • /content/denosumab-favored-over-alendronate-bmd-protection-glucocorticoid-induced-osteoporosis
  • /clinicianreviews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /familypracticenews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /internalmedicinenews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /obgynnews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /rheumatologynews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /clinicalendocrinologynews/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd
  • /obgyn/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection-glucocorticoid
  • /endocrinology/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /rheumatology/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /internalmedicine/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection
  • /familymedicine/article/231448/osteoporosis/denosumab-favored-over-alendronate-bmd-protection